| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00185-7400-14 | 00185-7400 | Leuprolide Acetate | Leuprolide Acetate | 1.0 mg/.2mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 6, 2011 | In Use | ||
| 43598-0308-23 | 43598-0308 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Nov 6, 2023 | In Use | |
| 25021-0416-01 | 25021-0416 | Plerixafor | Plerixafor | 20.0 mg/mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Aug 1, 2024 | In Use | |
| 62935-0452-45 | 62935-0452 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 23, 2002 | Apr 26, 2019 | No Longer Used | ||
| 50090-3466-00 | 50090-3466 | Goserelin acetate | ZOLADEX | 3.6 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 30, 2018 | In Use | ||
| 00004-0357-30 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Mar 29, 2011 | Jun 30, 2024 | No Longer Used |
| 71202-0012-11 | 71202-0012 | Denosumab | OSPOMYV | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 1, 2025 | Oct 31, 2025 | In Use |
| 83257-0029-41 | 83257-0029 | Denosumab-kyqq | BOSAYA | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jan 5, 2026 | In Use | |
| 15054-0120-01 | 15054-0120 | Lanreotide acetate | Somatuline Depot | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov 14, 2007 | Aug 31, 2016 | No Longer Used | |
| 00004-0357-99 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Aug 22, 2011 | Sep 19, 2014 | No Longer Used |
| 50242-0108-01 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 22, 2017 | In Use | |
| 15054-0060-01 | 15054-0060 | Lanreotide acetate | Somatuline Depot | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov 14, 2007 | Aug 31, 2016 | No Longer Used | |
| 61314-0866-01 | 61314-0866 | Pegfilgrastim-bmez | ZIEXTENZO | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | Subcutaneous | Nov 4, 2019 | Feb 28, 2026 | In Use |
| 00703-4014-11 | 00703-4014 | Leuprolide Acetate | Leuprolide Acetate | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov 6, 2000 | Mar 31, 2011 | No Longer Used | ||
| 73491-0627-01 | 73491-0627 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 23, 2023 | In Use | |
| 72893-0016-02 | 72893-0016 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 23, 2023 | In Use | |
| 82705-0002-01 | 82705-0002 | Epcoritamab-bysp | EPKINLY | 4.0 mg/.8mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Subcutaneous | May 19, 2023 | In Use | |
| 76282-0719-67 | 76282-0719 | LANREOTIDE ACETATE | LANREOTIDE ACETATE | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | May 30, 2025 | In Use | ||
| 63459-0920-59 | 63459-0920 | tbo-filgrastim | GRANIX | 480.0 ug/1.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 7, 2018 | Sep 30, 2026 | In Use |
| 15054-1060-03 | 15054-1060 | Lanreotide acetate | Somatuline Depot | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov 14, 2007 | Jun 30, 2022 | In Use | |
| 57894-0449-01 | 57894-0449 | Teclistamab-cqyv | TECVAYLI | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
| 00069-0291-01 | 00069-0291 | filgrastim-aafi | Nivestym | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sep 24, 2018 | In Use | |
| 63459-0912-36 | 63459-0912 | tbo-filgrastim | Granix | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Mar 2, 2015 | In Use | |
| 63459-0918-59 | 63459-0918 | tbo-filgrastim | GRANIX | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 7, 2018 | In Use | |
| 50242-0201-01 | 50242-0201 | Mosunetuzumab | Lunsumio Velo | 45.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Subcutaneous | Dec 19, 2025 | In Use |
Found 12482 results — Export these results
Home